Actavis, Watson divest products and candidates to Par to satisfy merger conditions
Executive Summary
To satisfy FTC conditions associated with Watson Pharmaceuticals Inc.’s $5.6bn purchase of privately held generics firm Actavis Group, the two companies have agreed to divest a total of 14 generics (marketed products, pending ANDAs, and a development project) to Par Pharmaceutical Cos. Inc., which paid an undisclosed sum in cash.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Alliance
- Product Purchase
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice